NCT05862324: An ongoing trial by Triumvira Immunologics, Inc.
This trial is ongoing. It must report results 2 years, 10 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05862324 |
|---|---|
| Title | A Phase 1/2 Study Investigating the Safety and Efficacy of Autologous TAC T Cells in Subjects With Unresectable, Locally Advanced or Metastatic Claudin 18.2+ Solid Tumors |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 23, 2023 |
| Completion date | Aug. 1, 2027 |
| Required reporting date | July 31, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Sept. 11, 2025 |
| Days late | None |